Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03453801 · ClinicalTrials.gov registry record · Phase 1

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

A Phase 1 study of Healthy and Influenza, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT03453801: Completed Phase 1 study of Healthy and Influenza, sponsored by Stanford University.

NCT03453801 is a Phase 1 study of Healthy and Influenza that has completed, run by Stanford University. The registered enrollment target is 80 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03453801, a Phase 1 study of Healthy and Influenza, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.

Primary Outcome

The percentage of cells with the various antigen-specific T memory phenotypes will be determined.

Conditions Studied

Interventions

  • BIOLOGICAL Fluzone®
  • BIOLOGICAL FluMist®

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2014-09-30
Est. Completion 2019-01-14
Phase Phase 1
Stanford University

1,744 total trials

What the finished NCT03453801 record still lists

NCT03453801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Fluzone® is the first listed.

NCT03453801 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03453801 about?

NCT03453801 is a clinical study titled "The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection". The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.

What is the current status of trial NCT03453801?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-09-30. Estimated completion is 2019-01-14.

What conditions does trial NCT03453801 study?

This clinical trial studies the following conditions: Healthy, Influenza.

What interventions are being tested in trial NCT03453801?

The interventions under investigation include: Fluzone® (BIOLOGICAL), FluMist® (BIOLOGICAL).

Who is sponsoring clinical trial NCT03453801?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03453801 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03453801's enrollment target sits among peer trials

80 274th of 1090 higher than 802 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03453801, the US trial registry maintained by the National Library of Medicine. NCT03453801 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.